ImmuPharma (LON:IMM) Trading 28.8% Higher - Here's Why

Key Points

• ImmuPharma's stock price surged by 28.8% during trading, reaching a high of GBX 15.23 ($0.21) before closing at GBX 13.98 ($0.19), indicating significant investor interest.
• The trading volume experienced a remarkable 451% increase from its average daily volume, with almost 44.75 million shares traded.
• ImmuPharma is a biopharmaceutical company specializing in peptide-based therapeutics, and its lead program targets treating Lupus with a drug known as Lupuzor™.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price shot up 28.8% during mid-day trading on Saturday . The company traded as high as GBX 15.23 ($0.21) and last traded at GBX 13.98 ($0.19). 44,749,293 shares changed hands during trading, an increase of 451% from the average session volume of 8,119,573 shares. The stock had previously closed at GBX 10.85 ($0.15).

ImmuPharma Stock Performance

The company has a market capitalization of £69.86 million, a P/E ratio of -1,570.67 and a beta of 1.53. The business has a 50 day moving average of GBX 3.12 and a 200-day moving average of GBX 2.92.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, equities analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.